Founded in 2018, Atropos is a biotechnology platform company focused on the discovery, development, and commercialization of therapies targeting the formation of senescent cells. The company leverages unexploited insights in senescence biology to discover agents and modalities. This disruptive approach to "aging" disorders targets that which is common to these diseases, the stress-induced accumulation of the senescent cell in various tissues.